Open-label, Randomized, Single Dose, 4period, Replicated, Cross-over Trial to Assess the Bioequivalence of Feniramidol HCl 400 mg Film Tablet in Comparison With Cabral 400 mg Film Tablet in Healthy Male Subjects Under Fed Conditions
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- AUCt-last
研究概览
简要总结
OPEN-LABEL, RANDOMISED, SINGLE ORAL DOSE, FOUR-PERIOD, REPLICATED, CROSS-OVER TRIAL TO ASSESS THE BIOEQUIVALENCE OF FENIRAMIDOL HCl 400 MG FILM TABLET (TEST DRUG) IN COMPARISON WITH CABRAL 400 MG FILM TABLET (REFERENCE DRUG) IN HEALTHY MALE SUBJECTS UNDER FED CONDITIONS
详细描述
Phenyramidol shows its muscle relaxant activity by interneuronal blockage without disrupting neuromuscular function. Thus, it relieves muscle spasm, and breaks pain-spasm chain by blocking polisynaptic reflexes in the brain and medulla spinalis. It does not affect monosynaptic reflexes.
Phenyramidol has a very high analgesic effect than aspirin and close to codeine. It used in the treatment of acute and chronic human musculoskeletal system pains as muscle relaxant and analgesic.
Pharmacokinetics Phenyramidol reaches maximum plasma concentration in an hour (0.25-1) after absorption from gastrointestinal tract. It is widely distributed in skeletal muscles and involved in circulatory system very slowly.
Studies have shown that cytochrome P450 enzymes are effective in phenyramidol metabolism. It is conjugated with glucuronic acid in the liver and it is excreted as glucuronide conjugates from the urinary tract. The drug is eliminated from the bile and the bacterial glucuronidase enzymes make the glucuronide conjugate of phenyramidol free. The drug enters enterohepatic circulation and is excreted by faeces. Its elimination half-life is 1-2 hours.
Indications Phenyramidol is indicated in the symptomatic treatment of acute painful muscle spasms associated with musculoskeletal system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Only volunteers fulfilling all of the following criteria should be enrolled in the present trial:
- •Healthy Caucasian male subjects aged between 18 and 55 years,
- •Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during each study period,
- •Negative alcohol breath test results,
- •Normal physical examination at screening visit,
- •Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,
- •Ability to communicate adequately with the investigator himself or his/her representatives,
- •Ability and agreement to comply with the study requirements,
- •Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,
- •Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,
- •Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),
- •Understanding of the study and agreement to give a written informed consent according to section 20.3.
排除标准
- •Volunteers presenting any of the following exclusion criteria will not be included in the trial:
- •Who have atopic constitution or asthma and/or known allergy for phenyramidol HCl or any other ingredients of the products.
- •Any history or presence of clinical relevance of cardiovascular, neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.
- •Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator).
- •Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
- •Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.
- •Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.
- •Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).
- •Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
- •History of allergic response to heparin.
- •Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.
- •Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.
- •Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study, or during the washout periods.
- •History of drug abuse.
- •History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).
- •Positive blood test for HBV, HCV and HIV.
- •Who have relationship to the investigator.
- •Who are not suitable to any of inclusion criteria.
- •History of difficulty of swallowing.
- •Intake of depot injectable solutions (including study medications) within 6 months before start of the study.
- •Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.
- •Special diet due to any reason, e.g. vegetarian.
研究组 & 干预措施
Phenyramydol then Cabral
Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
干预措施: Phenyramydol HCl 400 mg Film Tablet (Drug)
Phenyramydol then Cabral
Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
干预措施: Cabral 400 mg Film Tablet (Drug)
Cabral then Phenyramydol
Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
干预措施: Phenyramydol HCl 400 mg Film Tablet (Drug)
Cabral then Phenyramydol
Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
干预措施: Cabral 400 mg Film Tablet (Drug)
Phenyramydol then Cabral Replicate
Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
干预措施: Phenyramydol HCl 400 mg Film Tablet (Drug)
Phenyramydol then Cabral Replicate
Participants first receive Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state
干预措施: Cabral 400 mg Film Tablet (Drug)
Cabral then Phenyramydol Replicate
Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
干预措施: Phenyramydol HCl 400 mg Film Tablet (Drug)
Cabral then Phenyramydol Replicate
Participants first receive Cabral 400 mg Film Tablet manufactured by Recordati Ilac San ve Tİc A.S. in fed state. After a wash out period of 7 days, they then received Phenyramydol HCl 400 mg Film Tablet manufactured by Pharmactive Ilac San ve Tİc A.S.in fed state
干预措施: Cabral 400 mg Film Tablet (Drug)
结局指标
主要结局
AUCt-last
时间窗: 0 to 10 hours post-dose
AUC0-tlast of phenyramydol will be obtained from plasma concentrations
Cmax
时间窗: 0 to 10 hours post-dose
Cmax of phenyramydol will be obtained from plasma concentrations
AUC0-inf
时间窗: 0 to 10 hours post-dose
AUC0-inf of phenyramydol will be obtained from plasma concentrations
次要结局
- tmax(0 to 10 hours post-dose)